drugset

drugset / Trial / NCT00032929

Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1

NCT00032929 ↗

Phase 3 Completed 269 enrolled National Institute on Drug Abuse (NIDA) Somerset Pharmaceuticals · collab

RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the Selegiline Transdermal System for the treatment of cocaine dependence.

Timeline

Start: 2001-03
Primary completion: 2002-12
Completion: —

Publications

Results Elkashef A, Fudala PJ, Gorgon L, Li SH, Kahn R, Chiang N, Vocci F, Collins J, Jones K, Boardman K, Sather M. Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence. Drug Alcohol Depend. 2006 Dec 1;85(3):191-7. doi: 10.1016/j.drugalcdep.2006.04.010. Epub 2006 May 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Selegiline	Unknown	—	Other

Indications